DEFA14A: Orthofix Seeks Shareholder Approval for Incentive Plan Amendment to Attract and Retain Talent

Orthofix is requesting shareholder approval to increase the number of shares available under its 2012 Long-Term Incentive Plan by 5,000,000 shares to attract, retain, and motivate employees.

Summary

• Orthofix is seeking shareholder approval for Proposal 4 at the upcoming 2024 Annual Meeting of Shareholders.
• Proposal 4 involves amending the company's Amended and Restated 2012 Long-Term Incentive Plan (2012 LTIP) to increase the number of shares available by 5,000,000.
• The company believes these additional shares are crucial for granting equity awards to employees, attracting and retaining talent, and remaining competitive in the medical device industry.
• If the proposal is not approved, Orthofix anticipates facing challenges in recruiting and retaining skilled employees and may need to increase cash compensation, which would contradict their compensation philosophy and reduce resources for business needs.
• The Board estimates that the requested shares would provide for two years of employee equity grants at the current share price of approximately $13.50.
• The company emphasizes that the 2012 LTIP includes compensation and governance best practices, such as minimum vesting periods, restrictions on repricing, and administration by an independent committee.

Sentiment

Score: 7

Explanation: The document conveys a moderately positive sentiment, emphasizing the importance of the proposal for the company's future success and talent retention. However, it also acknowledges potential negative consequences if the proposal is not approved.

Positives

• The company believes that equity awards align employee and shareholder interests.
• The 2012 LTIP includes compensation and governance best practices, such as minimum vesting periods and restrictions on repricing.
• The plan is administered by an independent committee.
• The plan does not permit recycling shares withheld to cover taxes as available shares, which limits dilution.
• The company targets the median of the market for annual equity awards.

Negatives

• If Proposal 4 is not approved, the company may be at a disadvantage in recruiting and retaining talent.
• The company may be forced to increase cash compensation if the proposal is not approved, reducing resources for business needs.
• The burn rate in 2023 was higher than in prior years due to a pause in performance-based equity awards.

Risks

• Failure to secure shareholder approval for Proposal 4 could negatively impact the company's ability to attract and retain key employees.
• Increased reliance on cash compensation could strain financial resources and deviate from the company's compensation philosophy.
• If the share price increases, fewer shares would be required to be issued for equity awards to meet targeted equity compensation levels, reducing the dilutive impact to shareholders.

Future Outlook

The company aims to continue granting equity awards to eligible participants to attract, retain, and motivate employees, and remain competitive.

Management Comments

• The additional shares requested are critical to our ability to continue to grant equity awards to eligible participants, to attract, retain and motivate our most important asset, our valuable employees, and to remain competitive.
• If our shareholders do not approve Proposal 4, we believe that we will be at a disadvantage compared to our competitors for recruiting, retaining and motivating highly skilled employees, including members of our management team, as our competitors are implementing aggressive strategies to solicit and recruit top talents in the medical device industry.

Industry Context

The document highlights the competitive landscape in the medical device industry, where companies are aggressively recruiting top talent. Orthofix needs to offer competitive equity compensation packages to remain competitive.

Comparison to Industry Standards

• The company uses industry benchmarks to monitor and evaluate the reasonableness of the equity compensation they offer to their employees and prospective employees, targeting the median of the market for annual equity awards.
• The company benchmarks its peer group and targets the 50th percentile of the market.

Stakeholder Impact

• Shareholders: Approval of the proposal could lead to dilution, but the company argues it's necessary for long-term growth.
• Employees: Approval of the proposal would allow the company to continue offering competitive equity compensation packages.
• The company believes that awards granted under the 2012 LTIP will be a valuable incentive and will serve to the ultimate benefit of our shareholders by aligning more closely the interests of award recipients with those of our shareholders.

Next Steps

• Shareholders are urged to vote on Proposal 4 prior to the Annual Meeting.
• The company will continue to grant awards under the 2012 LTIP and the SeaSpine 2015 Plan until there are no longer any shares available for grant.

Key Dates

Keywords

incentive plan, equity awards, shareholder approval, compensation, talent retention, Orthofix, LTIP